NCT02458768已完成4 期
A Multicenter, Randomized, Open Label, Parallel Study to Evaluate the Efficacy & Safety of s.c. Administration of IVF-M HP Inj. Versus Menopur® Inj. in Infertility Women Undergoing Controlled Ovarian Hyperstimulation for Assisted Reproductive Technologies (ART) Such as in Vitro Fertilization-embryo Transfer (IVF-ET)
LG Life Sciences0 个研究点目标入组 112 人开始时间: 2013年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 112
- 主要终点
- Number of Retrieved Oocytes
研究概览
简要总结
The objective of this study was to demonstrate the non-inferiority of IVFM HP Inj. by evaluating its efficacy versus Menopur® Inj. in infertility women undergoing the in vitro fertilization and embryo transfer (IVF-ET) among the assisted reproductive technologies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 39 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Adult women from 20 through 39 years of age at the screening
- •Subjects with the mean menstrual cycle day (MCD) of 25 to 35 days
- •Subjects with the Follicle Stimulating Hormone (FSH) concentration at the screening not exceeding the upper limit of the normal range (ULN)
- •Those diagnosed with infertility due to at least one of the following causes of infertility
- •Fallopian tubal factor
- •Infertility due to unknown cause
- •Male infertility
- •Complex factor
- •Subjects with the normal ovarian and uterine function
- •Subjects with not more than 3 times of the prior experience of in vitro fertilization
- •Subjects who had neither administered clomiphene citrate within 30 days nor gonadotropin within 14 days of the IP administration day
- •Subjects who were informed on the objective, method and effect etc. of the clinical study and signed the informed consent form
排除标准
- •Subjects contraindicated to pregnancy
- •Subjects with BMI > 30 (BMI; kg/m2)
- •Subjects diagnosed with polycystic ovary syndrome (PCOS)
- •Subjects who had experienced previously at least Grade 4 ovarian hyperstimulation syndrome (OHSS)
- •Subjects with poor response to gonadotropin (According to the Bologna criteria* below) *At least two of the following three features must be present:
- •① Advanced maternal age (>=40 years) or any other risk factor for Poor Ovarian Response (POR)
- •② A previous POR (<=3 oocyte with a conventional stimulation protocol)
- •③ An abnormal ovarian reserve test (i.e. Antral follicle Count (AFC) < 5 follicles or Anti-Mullerian hormone (AMH) < 0.5 ng/ml)
- •Those with abnormal metrorrhagia due to unknown cause at the screening
- •Subjects with submucosal uterine leiomyoma
- •Subjects with at least borderline ovarian tumor
- •Subjects with a history or malignant tumor in breast
- •Subjects with hydrosalpinx not removed by operation
- •Subjects with the Thyroid Stimulating Hormone (TSH) level out of the normal range at the screening
- •Subjects with a history of malignant tumor within 5 years prior to the screening
- •Subjects with severe disease potentially affecting the study such as pituitary insufficiency upon the investigator's judgment (e.g., heart failure, renal failure, hepatic failure or adrenal insufficiency etc.)
- •Subject with HIV- or syphilis-positive result at the screening
- •Subjects with a psychiatric disorder at the screening or those who failed in understanding the objective and method of this clinical study
- •Subject diagnosed with alcohol or drug abuse within 3 months prior to the screening
- •Subjects with a history of hypersensitivity to the investigational products of this clinical study
- •Subjects with a current or history of thromboembolism in vein or artery
- •Subjects with a history of genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption etc.
- •Subjects who had participated in another clinical study related to a drug administration after the enrollment in this study or who had participated in another clinical study within 3 months prior to the enrollment in this study
- •Others including the subjects for whom it was considered difficult to conduct this clinical study upon the principal investigator's judgment
研究组 & 干预措施
IVF-M HP Inj.
Experimental
administration was initiated on the mean menstrual cycle day (MCD) 2 or 3 and made by subcutaneous injection.
Although the recommended initial dose of Investigational Product (IP) was 225 IU, adjustment was allowed according to the patient's individual response based on the monitoring (blood estradiol (E2) concentration and ultrasonography results).
干预措施: IVF-M HP Inj. (Drug)
Menopur® Inj.
Active Comparator
administration was initiated on the mean menstrual cycle day (MCD) 2 or 3 and made by subcutaneous injection.
Although the recommended initial dose of Investigational Product (IP) was 225 IU, adjustment was allowed according to the patient's individual response based on the monitoring (blood estradiol (E2) concentration and ultrasonography results).
干预措施: Menopur® Inj. (Drug)
结局指标
主要结局
Number of Retrieved Oocytes
时间窗: 36 hrs (±3 hrs) after administration of the ovulation stimulant
次要结局
未报告次要终点
研究者
相似试验
终止
4 期
A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological MalignancyHematologic NeoplasmsNCT02895529Xian-Janssen Pharmaceutical Ltd.61
尚未招募
4 期
Evaluate the Efficacy and Safety of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis PatientsAnemia in Incident Dialysis PatientsNCT04134026Second Xiangya Hospital of Central South University400
Unknown
不适用
Evaluation of the FIM - a Non Invasive Device for Temporarily and Quick Pupil Dilation (Mydriasis)Pupil DilationNCT01946828Tel-Aviv Sourasky Medical Center70
已完成
3 期
Treatment of Women After Severe Postpartum HaemorrhageSevere Postpartum HaemorrhageNCT01895205Pharmacosmos A/S13
已完成
不适用
ADenosine Vasodilator Independent Stenosis Evaluation II - ADVISE IICardiovascular DiseaseNCT01740895Volcano Corporation818